OMER
Omeros Corporation
There isn't enough reported data to score OMER yet.
OMER Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
OMER's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
OMER PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 1x | $1.76 | -90% |
| Fair | 5.3x | $9.22 | -49% |
| Forward | 5.5x | $17.99 | — |
| Expensive | 10x | $17.82 | -1% |
| Current | 10x | $17.99 | — |
Historical ranges are pointers, not guarantees.
OMER's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
OMER Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OMER to return to profit, with revenue growing. However, they disagree widely on these estimates.
OMER Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.25 | +88% |
| Q2 2026 | $1.73 | +$3.84 |
| Q1 2026 | $1.15 | +$3.80 |
| Q4 2025 | -$0.05 | +$2.65 |
| Q3 2025 | -$2.02 | +$0.28 |
| Q2 2025 | -$2.11 | +$0.23 |
| Q1 2025 | -$2.65 | -$0.69 |
| Q4 2024 | -$2.70 | -$0.83 |
| Q3 2024 | -$2.30 | -797% |
OMER has returned to profit: it earned $1.73 per share over the past year, after losing money the year before.
OMER Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2021 | $30M | +15% |
| Q2 2021 | $28.8M | +113% |
| Q1 2021 | $21.1M | -11% |
| Q4 2020 | $10.6M | -68% |
| Q3 2020 | $26.1M | -13% |
OMER's revenue is growing: $29M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 0.3% | N/A |
| Q1 2026 | -176% | N/A |
| Q3 2021 | -61% | +37 points |
| Q2 2021 | -83% | +121 points |
| Q1 2021 | -145% | -45 points |
| Q4 2020 | -318% | -247 points |
| Q3 2020 | -97% | -60 points |
| Q2 2020 | -205% | N/A |
OMER's operating margin was 0.3% last quarter, up 146 points from the same quarter a year ago, near the top of its range since 2019.
OMER Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.1M | +$26.1M |
| Q1 2026 | -$14.5M | +$21.4M |
| Q4 2025 | -$39.8M | -$10.8M |
| Q3 2025 | -$18.5M | +$13.6M |
| Q2 2025 | -$22M | +$24.1M |
| Q1 2025 | -$35.9M | +$6M |
| Q4 2024 | -$29M | +$5.9M |
| Q3 2024 | -$32.1M | +$621K |
OMER has burned cash in almost every quarter: −$69M over the past year, against −$119M the year before.
OMER Net Leverage
OMER Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.2 | Neutral |
| Stochastic | 62.7 | Neutral |
OMER's weekly RSI is 57 (neutral) and its Stochastic is 63 (neutral).
OMER PE vs Healthcare Sector
| Metric | OMER | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 85 | 29 | 56 pts above |
OMER is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OMER Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.1 | 0.5% below |
| 20 week MA | $16.0 | 13% above |
| 50 week MA | $13.4 | 34% above |
| 100 week MA | $9.89 | 82% above |
| 200 week MA | $7.06 | 155% above |
OMER's trend is up, with a small recent dip: it's below only its 8-week average, and 155% above its 200-week average.
OMER Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.0 | $14.9 | -0.7% |
| 2021 | $14.9 | $7.64 | -49% |
| 2022 | $7.64 | $2.54 | -67% |
| 2023 | $2.54 | $3.27 | +29% |
| 2024 | $3.27 | $11.7 | +257% |
| 2025 | $11.7 | $15.7 | +35% |
| 2026 YTD | $15.7 | $18.0 | +15% |
OMER's yearly returns have swung widely, from +257% in 2024 to −67% in 2022. It's up 15% so far in 2026.